Future Microbiology
Volume 19, 2024 - Issue 7: Future Microbiology
Drug Evaluation
Sulbactam–durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii
Sarah M McLeod1 Innoviva Specialty Therapeutics, Inc., an affiliate of Entasis Therapeutics Inc., 35 Gatehouse Drive, Waltham, MA 02451, USA
https://orcid.org/0009-0003-7827-794X
https://orcid.org/0009-0003-7827-794X, John P O'Donnell1 Innoviva Specialty Therapeutics, Inc., an affiliate of Entasis Therapeutics Inc., 35 Gatehouse Drive, Waltham, MA 02451, USAhttps://orcid.org/0000-0001-5502-8738
https://orcid.org/0000-0001-5502-8738, Navaneeth Narayanan2 Rutgers University Ernest Mario School of Pharmacy, Department of Pharmacy Practice & Administration, Piscataway, NJ 08901, USAhttps://orcid.org/0000-0001-5071-9193
https://orcid.org/0000-0001-5071-9193, John P Mills3 Division of Allergy, Immunology & Infectious Diseases, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USAhttps://orcid.org/0000-0001-6529-2911
https://orcid.org/0000-0001-6529-2911 & Keith S Kaye3 Division of Allergy, Immunology & Infectious Diseases, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USACorrespondence[email protected]
https://orcid.org/0000-0003-2051-1732
https://orcid.org/0000-0003-2051-1732